(Q44670941)

5 December 2017

title

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy (English)

1 reference

chronic inflammatory demyelinating polyradiculoneuropathy

5 December 2017

main subject

0 references

inflammation

0 references

author

Eduardo Nobile-Orazio

9

1 reference

5 December 2017

Paul McCrone

1

0 references

Martin Knapp

3

object named as

Martin Knapp

1 reference

5 December 2017

5

Giancarlo Comi

1 reference

5 December 2017

Daniel Chisholm

2

1 reference

5 December 2017

Richard Hughes

4

1 reference

5 December 2017

Marinos C Dalakas

6

1 reference

5 December 2017

Isabel Illa

7

1 reference

5 December 2017

Costas Kilindireas

8

1 reference

5 December 2017

Anthony Swan

10

1 reference

5 December 2017

Peter Van den Bergh

11

1 reference

5 December 2017

Hugh J Willison

12

1 reference

5 December 2017

INCAT Study Group

13

1 reference

5 December 2017

publication date

1 November 2003

1 reference

European Journal of Neurology

5 December 2017

published in

1 reference

5 December 2017

volume

10

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

687-694

1 reference

Analysis of cost data in randomized trials: an application of the non-parametric bootstrap

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Complications of intravenous immune globulin treatment in neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Resource costing for multinational neurologic clinical trials: methods and results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00701.X

10.1046/J.1351-5101.2003.00701.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference